GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BrainsWay Ltd.
BrainsWay is an Israeli medical company that has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. Its stock price reflects the pace of clinical adoption of this non-invasive therapy and its expanding use for other disorders.
Share prices of companies in the market segment - Psycho
BrainsWay (BWAY) develops and markets deep transcranial magnetic stimulation (Deep TMS) systems for the non-invasive treatment of depression and obsessive-compulsive disorder. We classify it under the "Psychiatry" category. The chart below shows the dynamics of the medical technology sector for treating brain disorders.
Broad Market Index - GURU.Markets
BrainsWay is an Israeli medical company that has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. As a component of the GURU.Markets index, it represents the neuromodulation sector. The chart below represents the entire market. See how BrainsWay shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BWAY - Daily change in the company's share price BrainsWay Ltd.
Shares of BrainsWay, a company developing brain therapies, are extremely volatile. Change_co measures the market's reaction to news of clinical trials and FDA approvals. This metric, while unspectacular in itself, is an indispensable component in building complex models for assessing risks and prospects in the MedTech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Psycho
BrainsWay Ltd. is a medical device company. This chart illustrates the high volatility of the MedTech industry. Comparing it to BWAY, which focuses on mental health treatments, helps us understand how its innovative products contribute to its volatility.
Daily change in the price of a broad market stock, index - GURU.Markets
BrainsWay is an Israeli medical technology company that developed deep transcranial magnetic stimulation (dTMS) technology for the treatment of depression and other disorders. The chart below shows volatility in the medical technology sector, allowing one to assess how the market is responding to BrainsWay's innovations.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BrainsWay Ltd.
BrainsWay Ltd.'s year-over-year performance reflects the adoption of its deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. Its market capitalization growth over the past 12 months reflects the growing number of clinics installing its equipment, confirming the recognition of this non-invasive method as an effective alternative to medication.
Annual dynamics of market capitalization of the market segment - Psycho
BrainsWay Ltd. is an Israeli medical company that has developed deep transcranial magnetic stimulation technology for the treatment of depression and other disorders. This chart shows how its innovative non-invasive therapy and efforts to expand its use are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BrainsWay, with its technology for non-invasive depression treatment, is a growth story in medicine. Its stock price is driven not by the economy, but by the speed of adoption by doctors and the insurance system. The chart reflects the potential of this breakthrough technology in the vast mental health market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BrainsWay Ltd.
BrainsWay, a medical device manufacturer, depends on the adoption of its technology for its market cap. The monthly fluctuations on the chart reflect the growth in installations of its transcranial magnetic stimulation systems, which are used to treat depression and OCD.
Monthly dynamics of market capitalization of the market segment - Psycho
BrainsWay has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other mental disorders. The company's success depends on the acceptance of this non-invasive method by doctors and patients. The psychotherapy equipment sector's performance reflects growing interest in innovative approaches to mental health.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BrainsWay develops non-invasive brain stimulation devices for the treatment of depression and other disorders. This is cutting-edge medical technology. The company's stock price performance is weakly correlated with the market, driven by news of regulatory approvals, clinical trial results, and the speed of adoption by physicians.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BrainsWay Ltd.
BrainsWay has developed a non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and OCD. Its weekly stock price reflects the pace of clinical adoption, insurance company coverage decisions, and competition from other mental health treatments.
Weekly dynamics of market capitalization of the market segment - Psycho
The neurotechnology sector, where BrainsWay operates, is driven by expectations for breakthrough treatments for mental disorders. The chart below reflects the general sentiment in this innovative niche. It allows one to assess how unique and in-demand BrainsWay's technology is perceived by the market compared to other companies' developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BrainsWay has developed a non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and OCD. The chart shows how much this medtech company's stock performance is driven by news of its technology's implementation, rather than by overall stock market sentiment.
Market capitalization of the company, segment and market as a whole
BWAY - Market capitalization of the company BrainsWay Ltd.
BrainsWay's market capitalization reflects investor sentiment about its non-invasive brain stimulation technology. The chart shows how the market values its deep TMS system for treating depression and OCD. Its growth reflects the growing acceptance of this technology as an alternative to medication and its adoption in psychiatric clinics.
BWAY - Share of the company's market capitalization BrainsWay Ltd. within the market segment - Psycho
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other mental disorders. Its market share in the psychotherapy equipment segment reflects the potential of this breakthrough technology. The company's market share reflects its bet that its method will become a viable alternative to drug treatment.
Market capitalization of the market segment - Psycho
This chart shows the total value of the entire psychotherapy equipment market. For BrainsWay, with its non-invasive magnetic brain stimulation technology, this line represents the future of psychiatry. The chart's growth reflects the search for alternatives to traditional antidepressants and investors' belief that technology can help treat brain disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
BrainsWay has developed a non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and other disorders. Its potential lies in evaluating its potential as an alternative to medication in psychiatry. This is the role of physical stimulation in improving brain function.
Book value capitalization of the company, segment and market as a whole
BWAY - Book value capitalization of the company BrainsWay Ltd.
BrainsWay Ltd. developed a non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of mental disorders. Its book value is derived from its technological assets: patents and a fleet of medical devices. This is its material foundation for helping patients. How has it grown? The chart below shows.
BWAY - Share of the company's book capitalization BrainsWay Ltd. within the market segment - Psycho
BrainsWay Ltd. has developed a non-invasive technology for treating mental disorders. Its business relies on manufacturing facilities in Israel, where its deep transcranial magnetic stimulation (Deep TMS) systems are assembled. The chart shows its share of the physical infrastructure for neuromodulation equipment production.
Market segment balance sheet capitalization - Psycho
BrainsWay, a manufacturer of non-invasive brain stimulation systems, is a capital-intensive business. It requires R&D and manufacturing capabilities to create its complex medical devices. The BCap_Seg chart for the medical equipment sector demonstrates just how "heavy" this industry is.
Book value of all companies included in the broad market index - GURU.Markets
BrainsWay's capital is not its drugs, but its patented transcranial magnetic stimulation (TMS) technology for treating depression and other brain disorders. The company's assets are its intellectual property and manufactured equipment. The chart shows the net worth of this neuromodulation innovator.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BrainsWay Ltd.
BrainsWay's balance sheet is its R&D and manufactured equipment. The market premium reflects the valuation of its transcranial magnetic stimulation (TMS) technology for treating mental disorders. The schedule is a bet on growing demand for non-drug treatments.
Market to book capitalization ratio in a market segment - Psycho
BrainsWay has developed a non-invasive technology for the treatment of depression and other brain disorders (TMS). The chart shows how investors view this innovative technology and its potential as a drug alternative, a huge market.
Market to book capitalization ratio for the market as a whole
BrainsWay develops medical devices using transcranial magnetic stimulation (TMS) to treat depression and other disorders. The company's value lies in its unique, approved technology. This chart shows how the market perceives its potential in the growing field of non-invasive neurostimulation.
Debts of the company, segment and market as a whole
BWAY - Company debts BrainsWay Ltd.
BrainsWay, a company developing transcranial magnetic stimulation systems for the treatment of depression and other disorders, is using the capital to commercialize its technology and conduct new clinical trials. This chart shows how the company is funding expanded access to its non-invasive treatment and exploring its application in new indications.
Market segment debts - Psycho
BrainsWay is an Israeli company that has developed deep transcranial magnetic stimulation (dTMS) technology for the treatment of depression and other brain disorders. Commercializing such innovative medical equipment requires significant investment. This chart shows how the company finances its sales and marketing efforts to penetrate the market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BrainsWay Ltd.
BrainsWay develops non-invasive brain stimulation devices for the treatment of depression and other disorders. This is cutting-edge medical technology. This chart shows the company's reliance on external funding for research and commercialization. It reflects the high financial risk inherent in companies bringing breakthrough medical technologies to market.
Market segment debt to market segment book capitalization - Psycho
BrainsWay has developed a non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and other brain disorders. This is an innovative approach in psychiatry. The chart shows the debt burden in the medical device sector, which helps assess how BrainsWay is funding the commercialization of its unique technology.
Debt to book value of all companies in the market
BrainsWay Ltd. developed a non-invasive technology for treating depression and other brain disorders, which required significant investment in clinical research. This chart shows the overall market debt burden. It helps assess how the company is managing its debt during the commercialization phase of its unique medical technology and pursuing profitability.
P/E of the company, segment and market as a whole
P/E - BrainsWay Ltd.
BrainsWay has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. This chart shows how the market is valuing its non-invasive treatment method. The trend reflects the growing acceptance of this technology and its potential to help patients who are not responding to medication.
P/E of the market segment - Psycho
BrainsWay is a manufacturer of non-invasive brain stimulation systems. This chart shows the average rating for the medical device sector. It shows the premium the market places on BrainsWay for its innovative depression treatment technology compared to more traditional medical device manufacturers.
P/E of the market as a whole
BrainsWay Ltd. has developed and markets non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. This chart reflects the overall sentiment in the medical technology sector. It helps us understand whether BWAY's high valuation stems from faith in its unique technology or is part of the industry's overall optimism.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BrainsWay Ltd.
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation (DTS) technology for the treatment of depression and other brain disorders. Future revenue depends on its clinical implementation. This chart reflects market expectations regarding the commercial success of this innovative treatment.
%20P%2FE%20BrainsWay%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BrainsWay-Ltd.&v=1772636129604 "Chart of the company's future (projected) P/E BrainsWay Ltd.")
Future (projected) P/E of the market segment - Psycho
BrainsWay has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and obsessive-compulsive disorder. This chart reflects expectations for its future profitability, indicating whether analysts believe this non-invasive treatment will be widely adopted in psychiatric practice.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Psycho&v=1772636129644 "Future (projected) P/E graph of the market segment - Psycho")
Future (projected) P/E of the market as a whole
BrainsWay has developed non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and other brain disorders. This chart of overall market expectations demonstrates investor appetite for breakthrough medical devices that offer new approaches to treating complex conditions.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636129680 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BrainsWay Ltd.
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. This graph shows the commercialization path for this innovative therapy. Revenue growth depends on the number of systems installed in clinics and the receipt of insurance coverage for the procedures.
Profit of companies in the market segment - Psycho
BrainsWay has developed and markets a non-invasive brain stimulation (TMS) system used to treat depression and other mental disorders. Its business operates at the intersection of medicine and neuroscience. The company's profitability depends on the acceptance of its technology by the medical community and insurance companies.
Overall market profit
BrainsWay is an Israeli company that has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other mental disorders. Demand is driven by medical needs, but the speed of adoption is influenced by economic factors. This schedule, reflecting the state of the healthcare system, affects clinics' ability to purchase expensive equipment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BrainsWay Ltd.
BrainsWay has developed a non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and OCD. This chart shows analysts' expectations for future profits. The forecast depends on the speed of adoption of their systems in psychiatric clinics and the expansion of insurance coverage for their therapeutic procedures.
%20profit%20of%20the%20company%20BrainsWay%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BrainsWay-Ltd.&v=1772636129888 "Graph of future (projected) profit of the company BrainsWay Ltd.")
Future (predicted) profit of companies in the market segment - Psycho
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. The profitability forecasts for the sector, shown in the graph, highlight the search for new treatments for mental illnesses. This chart helps assess the potential of BrainsWay's technology as an alternative to medication.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Psycho&v=1772636129992 "Graph of future (predicted) profits of companies in a market segment - Psycho")
Future (predicted) profit of the market as a whole
BrainsWay develops and markets non-invasive brain stimulation (TMS) systems for the treatment of depression and other mental disorders. Adoption of this technology depends on acceptance by the medical community and insurance companies. The positive economic environment, reflected in the chart, is stimulating investment in new medical technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636130049 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BrainsWay Ltd.
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. This chart shows how investors value the revenue from sales of its systems. The high valuation may reflect the great potential of this new approach to treating mental illness.
P/S market segment - Psycho
BrainsWay develops and markets non-invasive transcranial magnetic stimulation (TMS) systems for the treatment of depression and other brain disorders. This chart shows the average revenue estimate for the medical device sector. It helps understand the market premium for this innovative technology for treating mental illnesses.
P/S of the market as a whole
BrainsWay has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and obsessive-compulsive disorder. It is a non-invasive therapy for patients who are not responding to medication. The chart below compares how the market values the company's revenue with that of this innovative medical device.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BrainsWay Ltd.
BrainsWay has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. This chart shows how investors estimate its future revenue. This valuation is a bet on the wider adoption of this non-invasive therapy in psychiatric practice.
%20P%2FS%20BrainsWay%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BrainsWay-Ltd.&v=1772636130278 "The graph of the company's future (projected) P/S BrainsWay Ltd.")
Future (projected) P/S of the market segment - Psycho
BrainsWay has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. This chart compares the company's estimated future sales with other psychopharmaceutical companies, reflecting investor expectations for the clinical adoption of this non-invasive treatment method.
%20P%2FS%20market%20segment%20graph%20-%20Psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Psycho&v=1772636130337 "Future (projected) P/S market segment graph - Psycho")
Future (projected) P/S of the market as a whole
BrainsWay develops and markets non-invasive brain stimulation (TMS) systems for the treatment of depression and other mental disorders. Demand for its technology depends on acceptance in the medical community and insurance coverage. This overall growth expectation is less important for BrainsWay than the growing need for effective treatments for mental illnesses.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636130359 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BrainsWay Ltd.
Here's a revenue chart for BrainsWay, an Israeli company that developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. Revenue is generated from sales and leasing of its systems to medical institutions. Revenue growth reflects the growing acceptance of this non-invasive treatment as an alternative to drug therapy.
Sales of companies in the market segment - Psycho
BrainsWay has developed and markets a deep transcranial magnetic stimulation (Deep TMS) system for the treatment of depression and obsessive-compulsive disorder. This graph shows revenue in the psychotherapy sector. It reflects the growing demand for non-drug treatments for mental disorders, where BrainsWay's technology offers an innovative and effective alternative for patients.
Overall market sales
BrainsWay Ltd. has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. Demand for this non-invasive therapy is growing. Economic cycles, as reflected in this graph, do not directly affect treatment demand, but overall economic growth improves insurance coverage for such innovative procedures.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BrainsWay Ltd.
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other brain disorders. This projected revenue chart reflects the pace of adoption of this therapy. This growth is driven by expectations of an increasing number of clinics and patients using its system as an alternative to drug treatment.
%20sales%20of%20the%20company%20BrainsWay%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BrainsWay-Ltd.&v=1772636130513 "Schedule of future (projected) sales of the company BrainsWay Ltd.")
Future (projected) sales of companies in the market segment - Psycho
BrainsWay has developed and markets a deep transcranial magnetic stimulation (Deep TMS) system for the treatment of depression and obsessive-compulsive disorder in patients who have failed other therapies. This chart shows projected revenue for the entire psychotherapy sector, reflecting the search for new non-invasive treatments for mental illness.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Psycho&v=1772636130516 "Schedule of future (projected) sales of companies in the market segment - Psycho")
Future (projected) sales of the market as a whole
BrainsWay Ltd. has developed non-invasive transcranial magnetic stimulation (TMS) technology for the treatment of depression and other brain disorders. Demand for its technology is growing as awareness of mental health increases. A stable economy provides better insurance coverage for such innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636130611 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BrainsWay Ltd.
BrainsWay Ltd. has developed deep transcranial magnetic stimulation (dTMS) technology for the treatment of depression and other brain disorders. The company's profitability depends on sales or leasing of its systems to clinics. The graph shows how the company approaches operating profitability as its installed base grows.
Market segment marginality - Psycho
BrainsWay has developed and markets a non-invasive deep transcranial magnetic stimulation (Deep TMS) system for the treatment of depression and other mental disorders. This chart compares the profitability of its innovative medical device. The uniqueness of its technology and proven clinical effectiveness allow the company to maintain high margins on its equipment.
Market marginality as a whole
BrainsWay has developed transcranial magnetic stimulation (TMS) technology for the treatment of depression and other mental disorders. The need for effective treatments for mental illness is enormous and is not dependent on the state of the economy, as reflected in this chart. The company's success depends on physician acceptance of its technology and insurance coverage.
Employees in the company, segment and market as a whole
Number of employees in the company BrainsWay Ltd.
BrainsWay has developed non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other disorders. This chart shows its growing commercial team. The increase in staff reflects efforts to install systems in clinics and raise awareness among physicians and patients.
Share of the company's employees BrainsWay Ltd. within the market segment - Psycho
BrainsWay has developed deep transcranial magnetic stimulation (TMS) technology for the treatment of mental disorders. Its business requires a team of engineers to refine the device and clinical specialists to train doctors. This graph demonstrates its scale in the neurotechnology niche, reflecting its share of the talent pool working in this field.
Number of employees in the market segment - Psycho
BrainsWay has developed non-invasive deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. This graph illustrates the growth in innovative treatments for mental disorders. The growing number of clinicians and vendors reflects the growing recognition of this technology as an alternative to medication.
Number of employees in the market as a whole
BrainsWay develops and markets non-invasive brain stimulation (TMS) systems for the treatment of depression and other mental disorders. Its growth reflects the adoption of innovative technologies in psychiatry. This employment chart shows how the MedTech mental health sector is creating new jobs and changing treatment approaches.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BrainsWay Ltd. (BWAY)
BrainsWay Ltd. is an Israeli company that developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and other mental disorders. This chart demonstrates the company's high cost per employee. The market is evaluating the company's unique, patented technology and its potential in the vast mental health market.
%20of%20the%20company%20BrainsWay%20Ltd.%20(BWAY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BrainsWay-Ltd.-BWAY&v=1772636130946 "Chart of market capitalization per employee (in thousands of dollars) of the company BrainsWay Ltd. (BWAY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Psycho
BrainsWay develops and markets non-invasive brain stimulation devices for the treatment of depression and other mental disorders. In the field of advanced medical technologies, this indicator reflects the market's confidence in their innovation. A high value indicates that investors highly value the potential of their unique technology and its ability to transform patients' lives.
%20by%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Psycho&v=1772636131115 "Market capitalization per employee (in thousands of dollars) by market segment - Psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
BrainsWay has developed a non-invasive deep transcranial magnetic stimulation technology for the treatment of depression and other disorders. This figure reflects its high-tech medical business. The company's value lies in its unique, FDA-approved technology, which offers new hope to patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636131181 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BrainsWay Ltd. (BWAY)
BrainsWay Ltd. is an Israeli company that produces non-invasive brain stimulation (Deep TMS) equipment for the treatment of depression and OCD. This chart demonstrates the commercial success of this model. Their high profit per employee is a direct result of the high margins of their unique technology and the efficiency of their relatively small R&D and sales team.
%20Chart%20BrainsWay%20Ltd.%20(BWAY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BrainsWay-Ltd.-BWAY&v=1772636131194 "Company Profit Per Employee (in thousands of dollars) Chart BrainsWay Ltd. (BWAY)")
Profit per employee (in thousands of dollars) in the market segment - Psycho
BrainsWay is an Israeli company that produces non-invasive brain stimulation (Deep TMS) systems for the treatment of depression and OCD. It is a high-tech medical device. This indicator reflects the performance of their R&D and sales teams, which serve the highly specialized market of psychiatric equipment.
%20in%20the%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Psycho&v=1772636131218 "Chart of profit per employee (in thousands of dollars) in the market segment - Psycho")
Profit per employee (in thousands of dollars) for the market as a whole
BrainsWay is a company that developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. It is a MedTech company. This chart shows the balance between high R&D and clinical research costs and revenue from sales (or leasing) of expensive TMS devices to clinics and hospitals worldwide.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636131234 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BrainsWay Ltd. (BWAY)
BrainsWay develops and markets non-invasive brain stimulation (TMS) systems for the treatment of depression and other disorders. This chart shows how the company is commercializing its medical technology. Revenue per employee reflects the number of systems sold and the growth of their use in clinical practice.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BrainsWay-Ltd.-BWAY&v=1772636131264 "Sales chart per company employee BrainsWay Ltd. (BWAY)")
Sales per employee in the market segment - Psycho
BrainsWay (BWAY) is an Israeli company that has developed deep transmagnetic stimulation (Deep TMS) technology for the treatment of depression, OCD, and other brain disorders. This chart shows how much revenue each employee generates from the sale or rental of their systems. It's an indicator of the commercial success of their non-invasive technology in psychiatry.
Sales per employee for the market as a whole
BrainsWay Ltd. is an Israeli medtech company that produces deep transcranial magnetic stimulation (Deep TMS) systems for the treatment of depression and OCD. This metric reflects how successfully the company sells or leases its expensive systems to clinics and psychiatric centers, monetizing its R&D.
Short shares by company, segment and market as a whole
Shares shorted by company BrainsWay Ltd. (BWAY)
BrainsWay is an Israeli company that produces non-invasive brain stimulation (TMS) equipment for the treatment of depression and OCD. This chart reflects bearish bets. Bears may doubt the speed of commercial adoption of this expensive technology or its competitiveness compared to drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BrainsWay-Ltd.-BWAY&v=1772636131355 "Short Shares Chart for the Company BrainsWay Ltd. (BWAY)")
Shares shorted by market segment - Psycho
BrainsWay is an Israeli company that produces deep transcranial magnetic stimulation (Deep TMS) equipment for the treatment of depression and OCD. This indicator measures pessimism. "Short" here is a bet that their technology will not be widely accepted by doctors or that insurance companies will not cover it.
Shares shorted by the overall market
BrainsWay is an Israeli company that has developed non-invasive brain stimulation (TMS) technology for the treatment of depression and OCD. It's high-tech medicine. This chart measures overall market fear. When investors panic, they may avoid medical equipment stocks whose procedures are non-emergency and can be postponed by patients or clinics.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BrainsWay Ltd. (BWAY)
BrainsWay (BWAY) is an Israeli medical device company. They have developed deep transmagnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. This chart measures hype. It shows "overheated" (above 70) on news of expanding use of their technology or "oversold" (below 30) amid slow adoption or reimbursement issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BrainsWay-Ltd.-BWAY&v=1772636131446 "RSI 14 indicator chart for the company's stock BrainsWay Ltd. (BWAY)")
RSI 14 Market Segment - Psycho
BrainsWay (BWAY) is a "non-invasive" neuroscience company. They produce "helmets" (Deep TMS) for *magnetic stimulation* of the brain (treatment of depression, OCD). The RSI_14_Seg for "Psycho" (medtech) shows the overall sentiment. The chart helps us understand: is BWAY's volatility due to their technology, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
BrainsWay (BWAY) produces equipment for non-invasive brain stimulation (a treatment for depression). This chart shows that demand for its services is, unfortunately, "defensive." Market panic and recessions often exacerbate mental health issues. However, during a panic, hospitals (its clients) may "freeze" purchases of expensive equipment.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BWAY (BrainsWay Ltd.)
BrainsWay (BWAY) is an Israeli company that has developed deep transcranial magnetic stimulation (Deep TMS) technology for the treatment of depression and OCD. This chart shows the average target price. It reflects analysts' opinions on the rate of adoption of this non-invasive therapy in psychiatric clinics.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BWAY-BrainsWay-Ltd.&v=1772636131526 "A chart showing analyst consensus forecasts for the expected stock price. BWAY (BrainsWay Ltd.)")
The difference between the consensus estimate and the actual stock price BWAY (BrainsWay Ltd.)
BrainsWay is an Israeli medical technology company. They have developed a non-invasive technology called Deep Transmagnetic Stimulation (Deep TMS). Their device (a helmet with a coil) stimulates the brain and is used to treat drug-resistant severe depression and OCD. This chart shows analysts' confidence in the commercialization of this alternative therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BWAY-BrainsWay-Ltd.&v=1772636131581 "A chart showing the difference between the consensus forecast and the actual stock price. BWAY (BrainsWay Ltd.)")
Analyst consensus forecast for stock prices by market segment - Psycho
BrainsWay (BWAY) is an Israeli medical company that has developed deep transcranial magnetic stimulation (TMS) technology for the treatment of depression and OCD. This chart shows general expectations for the psychology sector. It reflects whether experts believe the market for non-drug therapies for mental disorders will grow.
Analysts' consensus forecast for the overall market share price
BrainsWay (BWAY) is an Israeli medical technology company that treats the brain from the outside in. They have developed deep transcranial magnetic stimulation (TMS) technology for the drug-free treatment of depression and OCD. This chart shows the overall risk appetite, reflecting the market's willingness to fund companies whose breakthrough medical technologies are changing the standards of psychiatry.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BrainsWay Ltd.
BrainsWay is a non-invasive medical technology company for psychiatry. They produce helmets (Deep TMS) that use magnetic brain stimulation to treat drug-resistant depression and OCD. This graph is a barometer of their adoption. It likely reflects their ability to sell or lease their expensive systems to psychiatric clinics and receive reimbursement from insurers.
AKIMA Market Segment Index - Psycho
BrainsWay (BWAY) is an Israeli medtech innovator in psychiatry; the company produces unique deep transcranial magnetic stimulation (Deep TMS) equipment for the treatment of depression and OCD. This composite metric evaluates companies. The graph shows the sector average. This benchmark: how does this breakthrough (TMS) technology (BWAY) differentiate it from the average medtech competitor?
The AKIM Index for the overall market
BrainsWay is a leader in non-invasive neurotherapy (Deep TMS) for the treatment of depression and OCD. It's an alternative to medication. This chart, reflecting the market average, is just a backdrop. It helps assess how this innovative company, expanding access to mental health, compares to overall economic trends and physician adoption of the technology.
